Pituitary adenomas are benign tumors, but still cause significant morbidity and in some cases increases in mortality. Surgical resection is not without risks, and approximately 40% of adenomas are incompletely resected. Medical therapies such as dopamine agonists, somatostatin analogues, and growth hormone antagonists are associated with numerous side effects. Understanding the molecular biology of pituitary adenomas may yield new therapeutic approaches. Additional studies are needed to help determine which genes or pathways are "drivers" of tumorigenesis and should be therapeutic targets. Further studies may also enable pituitary adenoma stratification to tailor treatment approaches.
Keywords: Corticotroph adenomas; Gonadotroph adenomas; Lactotroph adenomas; Molecular biology; Null cell adenomas; Pituitary adenomas; Somatotroph adenomas; Thyrotroph adenomas.
Copyright © 2019 Elsevier Inc. All rights reserved.